Thomas A. Wadden, PhD; Gregory K. Brown, PhD; Christina Egebjerg, PhD; et al.
This post hoc analysis of 4 randomized clinical trials evaluate the psychiatric safety of subcutaneous semaglutide, 2.4 mg, once weekly in people with obesity or overweight without known major psychopathology.